Oncology and Hematology

65-74 of 74

• 

  RestartResume

  Diversity in HER2 Expression Among Gynecologic Cancers 

  RestartResume

  Diversity in HER2 Expression Among Gynecologic Cancers 

  MinuteCE®

  Diversity in HER2 Expression Among Gynecologic Cancers 

  Ritu Salani, MD

  0.75 program credits

  • 

    

    Ritu Salani, MD

  0.75 program credits

• 

  RestartResume

  Patient Case: How Do HER2-Directed Therapies Fit Into the Ovarian Cancer Treatment Landscape?

  RestartResume

  Patient Case: How Do HER2-Directed Therapies Fit Into the Ovarian Cancer Treatment Landscape?

  MinuteCE®

  Patient Case: How Do HER2-Directed Therapies Fit Into the Ovarian Cancer Treatment Landscape?

  Ritu Salani, MD

  0.75 program credits

  • 

    

    Ritu Salani, MD

  0.75 program credits

• 

  RestartResume

  Patient Case: How Do HER2-Directed Therapies Fit Into the Biliary Tract Cancer Treatment Landscape?

  RestartResume

  Patient Case: How Do HER2-Directed Therapies Fit Into the Biliary Tract Cancer Treatment Landscape?

  MinuteCE®

  Patient Case: How Do HER2-Directed Therapies Fit Into the Biliary Tract Cancer Treatment Landscape?

  Ritu Salani, MD

  0.75 program credits

  • 

    

    Ritu Salani, MD

  0.75 program credits

• 

  RestartResume

  Pivotal Data on Targeting HER2 in HER2-Expressing Solid Tumors

  RestartResume

  Pivotal Data on Targeting HER2 in HER2-Expressing Solid Tumors

  MinuteCE®

  Pivotal Data on Targeting HER2 in HER2-Expressing Solid Tumors

  Shubham Pant, MD, MBBS

  0.75 program credits

  • 

    

    Shubham Pant, MD, MBBS

  0.75 program credits

• 

  RestartResume

  Significance of HER2 Expression in Solid Tumors    

  RestartResume

  Significance of HER2 Expression in Solid Tumors    

  MinuteCE®

  Significance of HER2 Expression in Solid Tumors    

  Shubham Pant, MD, MBBS; Ritu Salani, MD

  0.75 program credits

  • 

    

    Shubham Pant, MD, MBBS

  • 

    

    Ritu Salani, MD

  0.75 program credits

• 

  MinuteCE®

  Expanding Horizons: HER2 Targeting in Metastatic Solid Tumors

  Shubham Pant, MD, MBBS; Ritu Salani, MD

  0.75 credits 8 episodes

  • 

    

    Shubham Pant, MD, MBBS

  • 

    

    Ritu Salani, MD

  0.75 credits 8 episodes

• 

  RestartResume

  Monitoring and Managing Treatment-Related Adverse Effects Associated With HER2-Directed Agents

  RestartResume

  Monitoring and Managing Treatment-Related Adverse Effects Associated With HER2-Directed Agents

  MinuteCE®

  Monitoring and Managing Treatment-Related Adverse Effects Associated With HER2-Directed Agents

  Shubham Pant, MD, MBBS; Ritu Salani, MD

  0.75 program credits

  • 

    

    Shubham Pant, MD, MBBS

  • 

    

    Ritu Salani, MD

  0.75 program credits

• 

  RestartResume

  HER2 Testing Strategies Across Tumor Types Amidst Guidelines Gaps

  RestartResume

  HER2 Testing Strategies Across Tumor Types Amidst Guidelines Gaps

  MinuteCE®

  HER2 Testing Strategies Across Tumor Types Amidst Guidelines Gaps

  Shubham Pant, MD, MBBS

  0.75 program credits

  • 

    

    Shubham Pant, MD, MBBS

  0.75 program credits

• 

  RestartResume

  Emerging Data Evaluating HER2-Directed Therapies in Gynecologic Cancers

  RestartResume

  Emerging Data Evaluating HER2-Directed Therapies in Gynecologic Cancers

  MinuteCE®

  Emerging Data Evaluating HER2-Directed Therapies in Gynecologic Cancers

  Ritu Salani, MD

  0.75 program credits

  • 

    

    Ritu Salani, MD

  0.75 program credits

• 

  RestartResume

  HER2-Targeted ADCs in Advanced NSCLC: A Case-Based Approach to Targeted Treatment for Metastatic Disease

  RestartResume

  HER2-Targeted ADCs in Advanced NSCLC: A Case-Based Approach to Targeted Treatment for Metastatic Disease

  CME/CE

  HER2-Targeted ADCs in Advanced NSCLC: A Case-Based Approach to Targeted Treatment for Metastatic Disease

  Justin Gainor, MD; Jacob Sands, MD

  0.50 credits

  • 

    

    Justin Gainor, MD

  • 

    

    Jacob Sands, MD

  0.50 credits